| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2833 | 2014 |
| Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015 | 689 | 2015 |
| Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer R Hu, C Lu, EA Mostaghel, S Yegnasubramanian, M Gurel, C Tannahill, ... Cancer research 72 (14), 3457-3462, 2012 | 643 | 2012 |
| Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with … ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of Clinical Oncology 35 (19), 2149-2156, 2017 | 445 | 2017 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120-1129, 2019 | 314 | 2019 |
| Serial blood-based analysis of AR-V7 in men with advanced prostate cancer M Nakazawa, C Lu, Y Chen, CJ Paller, MA Carducci, MA Eisenberger, ... Annals of Oncology 26 (9), 1859-1865, 2015 | 185 | 2015 |
| Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study BA Teply, H Wang, B Luber, R Sullivan, I Rifkind, A Bruns, A Spitz, ... The Lancet Oncology 19 (1), 76-86, 2018 | 182 | 2018 |
| Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide ES Antonarakis, C Lu, B Luber, C Liang, H Wang, Y Chen, JL Silberstein, ... European urology 74 (2), 218-225, 2018 | 174 | 2018 |
| Decoding the androgen receptor splice variants C Lu, J Luo Translational andrology and urology 2 (3), 178, 2013 | 162 | 2013 |
| Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 Z Chen, D Wu, JM Thomas-Ahner, C Lu, P Zhao, Q Zhang, C Geraghty, ... Proceedings of the National Academy of Sciences 115 (26), 6810-6815, 2018 | 142 | 2018 |
| Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer F Furuya, C Lu, MC Willingham, S Cheng Carcinogenesis 28 (12), 2451-2458, 2007 | 122 | 2007 |
| Regulation of β-catenin by a novel nongenomic action of thyroid hormone β receptor CJ Guigon, LI Zhao, C Lu, MC Willingham, S Cheng Molecular and cellular biology, 2008 | 96 | 2008 |
| Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors C Lu, SY Cheng Journal of molecular endocrinology 44 (3), 143, 2010 | 85 | 2010 |
| Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer A Sharp, JC Welti, MBK Lambros, D Dolling, DN Rodrigues, L Pope, ... European urology 76 (5), 676-685, 2019 | 76 | 2019 |
| Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma C Lu, L Zhao, H Ying, MC Willingham, S Cheng Endocrinology 151 (4), 1929-1939, 2010 | 67 | 2010 |
| Novel junction-specific and quantifiable in situ detection of AR-V7 and its clinical correlates in metastatic castration-resistant prostate cancer Y Zhu, A Sharp, CM Anderson, JL Silberstein, M Taylor, C Lu, P Zhao, ... European urology 73 (5), 727-735, 2018 | 63 | 2018 |
| Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors F Furuya, C Lu, CJ Guigon, SY Cheng Steroids 74 (7), 628-634, 2009 | 62 | 2009 |
| Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer AJ Armstrong, J Luo, DM Nanus, P Giannakakou, RZ Szmulewitz, ... JCO precision oncology 4, 1285-1301, 2020 | 56 | 2020 |
| Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1) L Fozzatti, C Lu, DW Kim, JW Park, I Astapova, O Gavrilova, ... Proceedings of the National Academy of Sciences 108 (42), 17462-17467, 2011 | 54 | 2011 |
| Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer M Saji, K Narahara, SK McCarty, VV Vasko, KM La Perle, K Porter, ... Oncogene 30 (42), 4307-4315, 2011 | 54 | 2011 |
